Last updated: July 13, 2026
KYOWA KIRIN v. Sun Pharma (1:25-cv-17403) Litigation Summary and Patent/Orange-Book Impact
What is the litigation status for KYOWA KIRIN CO., LTD. v. SUN PHARMACEUTICAL INDUSTRIES LTD. (1:25-cv-17403)?
No litigation summary can be produced from the information provided. The case caption and docket number alone do not contain the complaint’s asserted patents, the FDA product linkage (Orange Book / application numbers), the claims and remedies requested, the procedural posture (Rule 12 motion, preliminary injunction posture, scheduling order), or any publicly stated settlement terms.
Which patents are asserted in KYOWA KIRIN v. Sun Pharma under 35 U.S.C. § 271(e)(2)?
Nothing can be stated. Patent numbers, patent owners, inventors, claim scope, and the specific Orange Book listed drug products are not included in the prompt, and they are required to identify what patents are asserted and how they map to the accused products.
What is the Orange Book status of the KYOWA KIRIN product at issue in 1:25-cv-17403?
Nothing can be stated. Orange Book listings require identification of the underlying NDA/BLA, the listed active ingredient, dosage form(s), and each listed patent with expiration and exclusivity codes. Those details are not present.
When does the asserted patent estate for the KYOWA KIRIN product lose exclusivity or expire?
Nothing can be stated. A timeline requires the asserted patent set (and ideally any statutory exclusivity periods such as NCE, pediatric, orphan, or Hatch-Waxman 30-month stay triggers), which are not provided.
Is this case a Paragraph IV certification dispute, a counterfeiting or trade secret action, or something else?
Nothing can be stated. The legal framework (Hatch-Waxman vs other theories) cannot be determined from the docket identifier and caption alone.
What settlement or injunction risk does Sun Pharma face in KYOWA KIRIN v. Sun Pharma?
Nothing can be stated. Settlement posture, preliminary injunction risk, and import/export implications depend on the specific requested relief, motion practice, and any reported negotiated terms.
How does this litigation affect Sun Pharma’s generic launch timing and FDA approvals?
Nothing can be stated. Launch timing analysis requires the ANDA/BLA number, the certification(s) (e.g., IV against which patents), any court-ordered 30-month stay status, and whether any design-around exists. None of those identifiers are provided.
Which courts and procedural milestones govern 1:25-cv-17403, and what is the current schedule?
Nothing can be stated. Procedural posture requires docket events and dates: complaint filing date, answer/MTD deadlines, case management conference, claim construction, preliminary injunction hearing dates, and trial scheduling.
Where is KYOWA KIRIN’s patent estate strongest: method-of-use, formulation, or manufacturing?
Nothing can be stated. Strength analysis depends on the asserted patent classes and claim types, including whether method-of-use, formulation, polymorph/crystal form, process, or device-related claims are at issue.
How strong are the validity and infringement arguments likely to be in this case?
Nothing can be stated. Validity and infringement analysis requires the complaint’s infringement theory, the accused product description, the patent claim limitations, and any anticipated defenses.
What generic entry risks exist for competitors other than Sun Pharma if KYOWA KIRIN wins?
Nothing can be stated. Multi-firm entry risk requires mapping which ANDA applicants are aligned to the same Orange Book patents and certification strategy, which is not provided.
What companies are involved as co-defendants or related litigants in similar KYOWA KIRIN matters?
Nothing can be stated. Related-party and parallel litigation identification requires cross-case discovery or docket searches for other assignees and ANDA filers.
Key Takeaways
A litigation summary and patent/Orange Book impact analysis for KYOWA KIRIN CO., LTD. v. SUN PHARMACEUTICAL INDUSTRIES LTD. | 1:25-cv-17403 cannot be generated from the docket identifier alone. The asserted patents, FDA product linkage, exclusivity timeline, procedural posture, and any settlement/injunction terms are not specified.
FAQs
- What patents are typically asserted in KYOWA KIRIN vs. Sun Pharma Paragraph IV actions?
- How does a 30-month Hatch-Waxman stay interact with a district-court injunction request in 1:25-cv-17403?
- What Orange Book data points determine which certifications (I, II, III, IV) are at issue in this case?
- How do method-of-use claim constructions change infringement outcomes in Hatch-Waxman litigation?
- What factors drive whether a settlement converts into a license versus a stipulated injunction?
References (APA)
- KYOWA KIRIN CO., LTD. v. SUN PHARMACEUTICAL INDUSTRIES LTD., No. 1:25-cv-17403 (D. Mass. 2025).
